Helix Biopharma Corp. (TSE:HBP) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Helix BioPharma Corp., a clinical-stage biopharmaceutical company, has announced a delay in filing its interim financial statements, originally due on March 1, 2024. The company has requested a voluntary management cease trade order, which, if approved, will restrict its executives from trading shares but will not affect public trading. Helix reassures that there are no undisclosed material changes or information and aims to complete the filings by May 18, 2024.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
